Utilising Genotype Informed Bayesian Dosing of Tacrolimus in Children Post Solid Organ Transplantation.

NCT06529536

Status	RECRUITING
Phase	Phase 4
Sponsor	Murdoch Childrens Research Institute
Enrollment	45 participants

Key Eligibility Criteria

Inclusion (4)

- Participants will be assigned to the prospective arm if treated at Royal Children's Hospital who are receiving a solid organ transplant (SOT) (excluding repeat graft in liver transplant recipients, or lung or intestinal transplant) and who will be on tacrolimus as one of the main immunosuppressants post-transplant.
- Age 1-18 years of age
- Kidney, liver or heart transplant recipients
- Participant and/or parent consent to the study (prospective arm only)

Exclusion (5)

- Previous liver transplant.
- Lung OR Intestinal transplant.
- Insufficient time before transplant for pharmacogenomic analysis (prospective arm only)
- Immunosuppressant regimen not containing tacrolimus immediate release product
- Known hypersensitivity to tacrolimus and/or its formulation.

Locations (1 total)

Royal Children's Hospital, Melbourne, Victoria, Australia